Roche Holding AG (ROG.VX) Wednesday said new research shows its prospective medicine pertuzumab is effective in fighting breast cancer, providing a welcome boost for the Swiss pharmaceutical giant after its blockbuster cancer drug Avastin lost its U.S. breast cancer label earlier this month.
The data, which will be presented at this year's Breast Cancer Symposium in San Antonio, includes results from a late-stage study of pertuzumab used in combination with Roche's cancer medicine Herceptin and chemotherapy docetaxel.
"The data shows that pertuzumab is effective and we plan to file the drug for health authority review this year," Stefan Frings, Head Medical Affairs Oncology at Roche, told Dow Jones Newswires. "Given the strong data, we also have started a full phase III trial," he said.
Pertuzumab, a drug that works by inhibiting growth of cancer-causing protein HER2, should help Roche protect sales of Herceptin, which is set to lose its patent in a few years time, analysts say. Herceptin is one of the Swiss firm's best-selling products, which together with cancer blockbusters Avastin and Rituxan generates the bulk of Roche's annual turnover.
The growth potential of Roche's cancer portfolio was recently questioned after U.S. regulators in November revoked the breast cancer label for Avastin in the U.S., criticizing the medicine's effectiveness and prompting Roche to cut its peak sales estimates for the therapy.
Some analysts expect pertuzumab to become a future sales driver and help Roche alleviate pressure from generic competitors once Herceptin loses its patent protection.
"Increased visibility on pertuzumab potential begins at the San Antonio Breast Cancer meeting in December 2011, and will increase during 2012," said Citigroup pharmaceutical analysts Andrew Baum.
Roche has so far only said that late stage data has shown that pertuzumab, in combination with other treatments, helped some breast cancer patients live "significantly" longer without their disease worsening. Sector specialists expect more details to come at the upcoming breast cancer conference, which starts on Dec. 6.
HER2 breast cancer is a common form of breast cancer. Around 20% of all breast cancer patients--about 1.4 million new cases are registered world-wide every year--are affected by this form of cancer.
While some analysts remain skeptical about the drug's chances to win approval due to safety and efficiency concerns, some, like Bank Vontobel, expect the medicine to reach sales of close to $2 billion.
Another issue for analysts is the quality of the data, as Roche is using progression-free survival, or PFS, data to highlight the drug's effectiveness. Unlike overall survival rate, which denotes a percentage of patients who still live after taking a drug within a pre-defined period, PFS is the length of time during and after medication when the disease being treated doesn't get worse. Regulators have become wary of PFS, especially for first-line treatments.
"Progression free survival is a meaningful primary endpoint and a direct measure of the drug's effect," said Roche's Frings. "The data is quicker to measure, the drugs can potentially reach patients faster, and the outcome is not confounded by subsequent treatment lines," he said.
-By Goran Mijuk, Dow Jones Newswires, +41 43 443 80 47; goran.mijuk@dowjones.com
Recent RHHBY News
- Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives • AllPennyStocks.com • 09/10/2024 10:53:00 PM
- Roche's Cancer Injection Tecentriq SC Gets European Commission Approval • Dow Jones News • 01/16/2024 06:49:00 AM
- Beyond Diabetes, a Blockbuster Horizon Beckons • InvestorsHub NewsWire • 01/10/2024 01:45:00 PM
- LumiraDx Agrees to Sell Point-of-Care Tech Platform to Roche • Dow Jones News • 12/29/2023 10:07:00 PM
- Roche's Xolair Granted FDA Priority Review • Dow Jones News • 12/19/2023 03:27:00 PM
- Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment • Dow Jones News • 12/11/2023 03:31:00 PM
- Roche Obtains Positive Data on Early-Stage Breast Cancer Treatment • Dow Jones News • 12/08/2023 05:56:00 PM
- Roche's Inavolisib Breast Cancer Drug Gets Positive Results • Dow Jones News • 12/08/2023 05:38:00 PM
- Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials • Dow Jones News • 12/06/2023 10:14:00 AM
- Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage Study • Dow Jones News • 12/05/2023 06:54:00 AM
- Trending: Roche to Buy Carmot Therapeutics in Deal Worth Up to $3.1 Billion • Dow Jones News • 12/04/2023 03:12:00 PM
- Roche to Buy Carmot Therapeutics for Up to $3.1 Billion in Bet on Obesity Treatments -- Update • Dow Jones News • 12/04/2023 11:34:00 AM
- Alaska Air Acquires Hawaiian Holdings, Spotify Cuts 1,500 Jobs, Uber’s S&P 500 Entry, and More • IH Market News • 12/04/2023 10:55:07 AM
- Roche Strikes Deal to Buy Drug Developer Carmot Therapeutics for $2.7 Billion • Dow Jones News • 12/04/2023 06:47:00 AM
- Roche's Genentech, Nvidia Team Up to Accelerate Drug Discovery With AI • Dow Jones News • 11/21/2023 04:06:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2023 10:14:35 PM
- Roche Says Late-Stage Muscular Dystrophy Trial Didn't Meet Main Goal • Dow Jones News • 10/31/2023 06:26:00 AM
- Roche Gets FDA Approval for Vabysmo as Retinal Vein Occlusion Treatment • Dow Jones News • 10/27/2023 05:40:00 AM
- Trending: Roche to Buy Telavant From Roivant and Pfizer • Dow Jones News • 10/23/2023 07:41:00 PM
- Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- Update • Dow Jones News • 10/23/2023 08:16:00 AM
- Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion Deal • Dow Jones News • 10/23/2023 05:50:00 AM
- Roche Shares Fall on Lower Sales Due to Currency Hit • Dow Jones News • 10/19/2023 09:55:00 AM
- Roche Backs Guidance After Sales Fall • Dow Jones News • 10/19/2023 05:48:00 AM
- Roche Lung Cancer Drug Reduced Risk of Recurrence, Death in Late-Stage Trial • Dow Jones News • 10/18/2023 06:14:00 AM
- Roche's Elecsys IL-6 Test Approved for Diagnosis of Neonatal Sepsis • Dow Jones News • 10/18/2023 05:54:00 AM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM